Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patents worth Zero? Huh.
Shhh, don't tell that to the cats who loaned DCTH $10M last year used that IP as collateral.
Some days, I don't know what planet you are from.
P.S. DCTH to $370!!!
LoL. You are not new here. You posted on this message board no less than 10 times this month.
I just don’t have the energy or time to deal with all of this tomfoolery.
Know what you own. I know I do.
No. It was, I recall, around $.03 prior to the split, not $.15.
You presume people are stupid. That’s on you. I am pumping nothing. I am simply reposting company issued PRs and a single article. Each have a link.
This will be the first and last time I address this issue.
Good day.
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
Trump presses key Republican to move on ‘right to try’
https://www.statnews.com/2018/02/14/trump-walden-right-to-try/
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.
https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899
Let’s end the week on a high note, DCTH.
Nothing about Delcath's drug portfolio has changed since this article was written. Nothing.
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Jul.10.17 | About: Delcath Systems, (DCTH)
Jesse Donovan
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors
Delcath Announces Third Quarter 2017 Financial Results
Highlights from the third quarter of 2017 and recent weeks include:
· Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
· Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
· Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
· Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September
http://delcath.com/reuters-news/?id=2317164
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
DCTH 10K and year-end results will be filed within the next three weeks (no later than 16 March 2018).
Regarding the timing of our 10K filing and year-end results, SEC provides 75 days after fiscal year end to file a 10K, and we expect to file and release our 2017 year-end results within that window.
Regards,
Delcath Investor Relations
investorrelations@delcath.com
www.delcath.com
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients.
Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
Trump presses key Republican to move on ‘right to try’
https://www.statnews.com/2018/02/14/trump-walden-right-to-try/
The prior CEO planned to use use CHEMSAT 2.0 delivery system to treat other liver and colon cancers. That’s $2.5 billion market. I have no reason to believe Jenny will deviate from that strategy.
Plus, FDA approval essentially doubles market overnight.
Getting closer and closer to ‘Right to Try’ approval is the US.
If you need any additional info, please feel free to scroll through my prior posts.
Have a nice day.
I believe RS is a bluff. We’ll know more once Schedule 13 is filed hopefully in the next 2-3 days.
Meanwhile it looks like MAXM and CDEL continue to play Jabba the Hutt, sitting on the ask eating their bowl of frogs, making sure any organic momo is held in check.
Back to work.
He is a swamp creature.
Akika has dropped the ‘hahahahahahahahaha’s’ for a new maniacal laugh.
Take note: the long awaited reversal begins.
Trump presses key Republican to move on ‘right to try’
https://www.statnews.com/2018/02/14/trump-walden-right-to-try/
LOL. FINRA indicates 36,000 share equity short position. If I were you I’d splurge on a cheeseburger Happy Meal this time!
HULK LIKE GREEN!!!
I wonder how many shares they have left? The PR a few weeks back had HB and Ayerton with only 15M-20M shares (combined) left to convert. At this point, I have to believe they've darn near exhausted those given the high daily volume over the past two weeks.
To your point, the moment MAXM or CDEL waive off for 30 mins or more the stock turns north organically. The trading pattern since the reverse split is curious, to say the least.
I am tired of walking through any number of plausible scenarios. I've got the time and the faith because I think great things are ahead. Remember, each trading day brings us one day closer to FDA approval!!! IT'S NOT IF, IT'S WHEN, BABY!!!
HULK LIKE SAMUEL MUCH
HULK LIKE GREEN MORE THAN SAMUEL
HULK PREDICT GREEN CLOSE
The private placement prohibits the sale of the common stock until April and most of the stock converted was exhausted per filings.
The equity short interest from 1/31 was peanuts per FINRA, so I am genuinely confused.
We’ll get a new FINRA update next Tuesday so perhaps that will explain.
In any event, Good luck all!
It’s a curious thing. Citadel and Maxim group look as if there is a coordinated effort to control price. Maybe I just need to take off my tinfoil hat, but I’ve been watching this almost daily for months.
We’ll close green little! When does Sam appear? I give it maybe 15 mins? Lol. Soooo predictable.
Hasn’t been MAXM for a few weeks. It’s CDEL.
HULK LIKE GREEN.
Dear Sir,
Thank you for your inquiry. Schedule 13 filings are the responsibility of the individual shareholders. Please continue to monitor all filings made with the SEC as they are made for additional information.
Regards,
Delcath Investor Relations
Haha. The army of DCTH rabble. Love it!
Amen, Kid.
What’s all this jibber jabber in the past tense? Come on fellas, this beast has yet to stir!!!
Each passing day brings us closer to FDA approval. The long game baby!
GLTYA.
HULK LIKE POWER 24 MINS!!!
HULK LIKE HAIKU BEST.
HULK LIKE POETRY.
HULK LIKE GREEN!!!
Golf clap!
I came to ball, Sammy.
If it goes to $.0001 I lost my 2018 beer fund.
If she goes where I believe she will, it will be glorious. I think a castle in the Loire Valley might be too ostentatious, though. The last thing I want is to appear nouveau riche.
QUELLE HORREUR!
I sure hope so! I'd like to know who paid DCTH $3,600,000 for the 180M shares so I can shake their hands!